Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma-Reference-Cited by-同舟云学术

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma

Published:2022-06 Issue:6 Volume:17 Page:779-792
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Vokes Natalie I.,Chambers Emily,Nguyen Tom,Coolidge Alexis,Lydon Christine A.,Le Xiuning,Sholl Lynette,Heymach John V.,Nishino Mizuki,Van Allen Eliezer M.,Jänne Pasi A.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference48 articles.

1. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020

2. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers;Yu;Clin Cancer Res,2013

3. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer;Soria;N Engl J Med,2018

4. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain;Pao;PLoS Med,2005

5. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation;Oxnard;Clin Cancer Res,2011

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study;Journal of Clinical Oncology;2024-09-10

2. Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations;Hereditary Cancer in Clinical Practice;2024-08-19

3. ‘Plasma first’ approach for detecting epidermal growth factor receptor mutation in advanced non-small cell lung carcinoma;Journal of Cancer Research and Clinical Oncology;2024-07-27

4. PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC;Clinical Cancer Research;2024-07-17

5. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling;Nature Communications;2024-06-13